UA67741C2 - Солюбілізовані композиції сертраліну - Google Patents

Солюбілізовані композиції сертраліну Download PDF

Info

Publication number: UA67741C2
Authority: UA; Ukraine
Prior art keywords: sertraline; solubilizing agent; item; composition; composition according
Prior art date: 1997-07-01

Application number

UA99116391A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Дуейн Томас Фрізен

Скотт Макс Хербіг

Раві Майсор Шенкер

Джеймс Блеер Вест

Original Assignee

Пфайзер Продактс Інк.

Пфайзер Продактс Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-01

Filing date

1998-06-15

Publication date

2004-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA67741(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-15 Application filed by Пфайзер Продактс Інк., Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Інк.

2004-07-15 Publication of UA67741C2 publication Critical patent/UA67741C2/uk

Links

VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title claims abstract description 132
229960002073 sertraline Drugs 0.000 title claims abstract description 126
239000000203 mixture Substances 0.000 title claims abstract description 73
239000002904 solvent Substances 0.000 claims abstract description 90
239000002552 dosage form Substances 0.000 claims description 51
150000003839 salts Chemical class 0.000 claims description 39
150000007524 organic acids Chemical class 0.000 claims description 33
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
-1 chlorine ions Chemical class 0.000 claims description 28
238000012360 testing method Methods 0.000 claims description 25
229940093915 gynecological organic acid Drugs 0.000 claims description 22
235000005985 organic acids Nutrition 0.000 claims description 22
239000002609 medium Substances 0.000 claims description 21
238000000034 method Methods 0.000 claims description 21
239000000460 chlorine Substances 0.000 claims description 20
229910052801 chlorine Inorganic materials 0.000 claims description 20
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 20
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 17
125000005456 glyceride group Chemical group 0.000 claims description 15
239000011780 sodium chloride Substances 0.000 claims description 15
239000000605 aspartame Substances 0.000 claims description 14
229960003438 aspartame Drugs 0.000 claims description 14
238000013270 controlled release Methods 0.000 claims description 14
108010011485 Aspartame Proteins 0.000 claims description 13
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
235000010357 aspartame Nutrition 0.000 claims description 13
229920001223 polyethylene glycol Polymers 0.000 claims description 11
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
239000002202 Polyethylene glycol Substances 0.000 claims description 10
235000010323 ascorbic acid Nutrition 0.000 claims description 10
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 10
239000011668 ascorbic acid Substances 0.000 claims description 8
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 8
229960005070 ascorbic acid Drugs 0.000 claims description 7
230000000052 comparative effect Effects 0.000 claims description 7
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
150000001298 alcohols Chemical class 0.000 claims description 5
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 5
239000001639 calcium acetate Substances 0.000 claims description 5
235000011092 calcium acetate Nutrition 0.000 claims description 5
229960005147 calcium acetate Drugs 0.000 claims description 5
229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
150000005323 carbonate salts Chemical class 0.000 claims description 5
210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
239000004220 glutamic acid Substances 0.000 claims description 5
229940068939 glyceryl monolaurate Drugs 0.000 claims description 5
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 5
229920000056 polyoxyethylene ether Polymers 0.000 claims description 5
229920001451 polypropylene glycol Polymers 0.000 claims description 5
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
239000012736 aqueous medium Substances 0.000 claims description 4
229960004106 citric acid Drugs 0.000 claims description 4
235000015165 citric acid Nutrition 0.000 claims description 4
235000013922 glutamic acid Nutrition 0.000 claims description 4
229960002989 glutamic acid Drugs 0.000 claims description 4
229940087068 glyceryl caprylate Drugs 0.000 claims description 4
150000002334 glycols Chemical class 0.000 claims 8
150000002148 esters Chemical class 0.000 claims 5
239000000783 alginic acid Substances 0.000 claims 4
229920000615 alginic acid Polymers 0.000 claims 4
229960001126 alginic acid Drugs 0.000 claims 4
235000010443 alginic acid Nutrition 0.000 claims 4
150000004781 alginic acids Chemical group 0.000 claims 4
239000001509 sodium citrate Substances 0.000 claims 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
239000000600 sorbitol Substances 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 11
239000000243 solution Substances 0.000 description 32
239000000546 pharmaceutical excipient Substances 0.000 description 27
239000003826 tablet Substances 0.000 description 27
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 20
239000011257 shell material Substances 0.000 description 16
239000000499 gel Substances 0.000 description 14
239000002253 acid Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
238000005755 formation reaction Methods 0.000 description 11
230000003381 solubilizing effect Effects 0.000 description 11
239000000463 material Substances 0.000 description 10
239000011248 coating agent Substances 0.000 description 9
238000000576 coating method Methods 0.000 description 9
238000004090 dissolution Methods 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
239000008187 granular material Substances 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000012085 test solution Substances 0.000 description 7
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
229960003660 sertraline hydrochloride Drugs 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000013265 extended release Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000008101 lactose Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000003204 osmotic effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
229930091371 Fructose Natural products 0.000 description 4
239000005715 Fructose Substances 0.000 description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
159000000007 calcium salts Chemical class 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
239000012458 free base Substances 0.000 description 3
238000001879 gelation Methods 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
239000000523 sample Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
150000000996 L-ascorbic acids Chemical class 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical class OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000473 propyl gallate Substances 0.000 description 2
235000010388 propyl gallate Nutrition 0.000 description 2
229940075579 propyl gallate Drugs 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
239000012488 sample solution Substances 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
KSJDOQFYNPUQDU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O KSJDOQFYNPUQDU-JJKGCWMISA-N 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
241000218642 Abies Species 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000010167 Allium cepa var aggregatum Nutrition 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000209035 Ilex Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100498160 Mus musculus Dach1 gene Proteins 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
208000037036 Witteveen-Kolk syndrome Diseases 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
229940091181 aconitic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229940125709 anorectic agent Drugs 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007872 degassing Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
235000010350 erythorbic acid Nutrition 0.000 description 1
239000004318 erythorbic acid Substances 0.000 description 1
229940073505 ethyl vanillin Drugs 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
229940113174 imidurea Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940026239 isoascorbic acid Drugs 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940058352 levulinate Drugs 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000012057 packaged powder Substances 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
229940068917 polyethylene glycols Drugs 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA99116391A 1997-07-01 1998-06-15 Солюбілізовані композиції сертраліну UA67741C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5141397P	1997-07-01	1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en)	1997-07-01	1998-06-15	Solubilized sertraline compositions

Publications (1)

Publication Number	Publication Date
UA67741C2 true UA67741C2 (uk)	2004-07-15

Family

ID=21971159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99116391A UA67741C2 (uk)	1997-07-01	1998-06-15	Солюбілізовані композиції сертраліну

Country Status (34)

Country	Link
EP (1)	EP0999829A1 (no)
JP (1)	JP2000514100A (no)
KR (1)	KR100366373B1 (no)
CN (1)	CN1261794A (no)
AP (1)	AP1192A (no)
AR (3)	AR015917A1 (no)
AU (1)	AU742535B2 (no)
BG (1)	BG103918A (no)
BR (1)	BR9810739A (no)
CA (1)	CA2290974C (no)
CO (1)	CO4940495A1 (no)
DZ (1)	DZ2548A1 (no)
EA (1)	EA002481B1 (no)
HN (1)	HN1998000102A (no)
HR (1)	HRP980377A2 (no)
HU (1)	HUP0002236A3 (no)
ID (1)	ID23429A (no)
IL (1)	IL133076A (no)
IS (1)	IS5260A (no)
MA (1)	MA24587A1 (no)
NO (1)	NO996520L (no)
OA (1)	OA11243A (no)
PA (1)	PA8454301A1 (no)
PE (1)	PE97199A1 (no)
PL (1)	PL337804A1 (no)
SK (1)	SK181099A3 (no)
TN (1)	TNSN98124A1 (no)
TR (1)	TR199903297T2 (no)
TW (1)	TW550087B (no)
UA (1)	UA67741C2 (no)
UY (1)	UY25071A1 (no)
WO (1)	WO1999001120A1 (no)
YU (1)	YU68299A (no)
ZA (1)	ZA985708B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003518485A (ja)	1999-12-23	2003-06-10	ファイザー・プロダクツ・インク	向上された薬物濃度を与える医薬組成物
US20030086972A1 (en) *	2000-08-09	2003-05-08	Appel Leah E.	Hydrogel-driven drug dosage form
WO2002017918A2 (en)	2000-08-30	2002-03-07	Pfizer Products Inc.	Sustained release formulations for growth hormone secretagogues
US20040191207A1 (en) *	2003-03-31	2004-09-30	Lipari John M.	Alpha-hydroxy acid ester drug delivery compositions and methods of use
KR101500020B1 (ko) *	2007-03-12	2015-03-06	디에스엠 아이피 어셋츠 비.브이.	미용 조성물
EP2520299A1 (en) *	2009-12-29	2012-11-07	Kowa Co., Ltd.	Solid pharmaceutical composition for oral administration
EP2520300A4 (en) *	2009-12-29	2013-05-08	Kowa Co	PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
CN109908354A (zh) *	2017-12-12	2019-06-21	万特制药(海南)有限公司	盐酸舍曲林口服浓缩液及其制备工艺
CN114894736A (zh) *	2022-05-20	2022-08-12	中化地质矿山总局地质研究院	一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4803076A (en) *	1986-09-04	1989-02-07	Pfizer Inc.	Controlled release device for an active substance
EP0415612B1 (en) *	1989-08-30	1993-11-10	Pfizer Inc.	Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) *	1996-04-05	1997-08-18	Alza Corp	Uniform drug delivery theraphy.

1998
- 1998-06-15 UA UA99116391A patent/UA67741C2/uk unknown
- 1998-06-15 CN CN98806763A patent/CN1261794A/zh active Pending
- 1998-06-15 PL PL98337804A patent/PL337804A1/xx unknown
- 1998-06-15 CA CA002290974A patent/CA2290974C/en not_active Expired - Fee Related
- 1998-06-15 KR KR10-1999-7011361A patent/KR100366373B1/ko not_active IP Right Cessation
- 1998-06-15 TR TR1999/03297T patent/TR199903297T2/xx unknown
- 1998-06-15 BR BR9810739-9A patent/BR9810739A/pt not_active Application Discontinuation
- 1998-06-15 WO PCT/IB1998/000933 patent/WO1999001120A1/en not_active Application Discontinuation
- 1998-06-15 EA EA199900962A patent/EA002481B1/ru unknown
- 1998-06-15 EP EP98923019A patent/EP0999829A1/en not_active Withdrawn
- 1998-06-15 YU YU68299A patent/YU68299A/sh unknown
- 1998-06-15 ID IDW991701A patent/ID23429A/id unknown
- 1998-06-15 SK SK1810-99A patent/SK181099A3/sk unknown
- 1998-06-15 HU HU0002236A patent/HUP0002236A3/hu unknown
- 1998-06-15 IL IL13307698A patent/IL133076A/xx not_active IP Right Cessation
- 1998-06-15 JP JP11506774A patent/JP2000514100A/ja active Pending
- 1998-06-15 AU AU75448/98A patent/AU742535B2/en not_active Ceased
- 1998-06-25 TW TW087110267A patent/TW550087B/zh active
- 1998-06-25 AP APAP/P/1998/001280A patent/AP1192A/en active
- 1998-06-26 PE PE1998000573A patent/PE97199A1/es not_active Application Discontinuation
- 1998-06-29 PA PA19988454301A patent/PA8454301A1/es unknown
- 1998-06-29 UY UY25071A patent/UY25071A1/es not_active IP Right Cessation
- 1998-06-29 AR ARP980103146A patent/AR015917A1/es not_active Application Discontinuation
- 1998-06-30 ZA ZA9805708A patent/ZA985708B/xx unknown
- 1998-06-30 TN TNTNSN98124A patent/TNSN98124A1/fr unknown
- 1998-06-30 DZ DZ980158A patent/DZ2548A1/xx active
- 1998-06-30 MA MA25146A patent/MA24587A1/fr unknown
- 1998-07-01 HN HN1998000102A patent/HN1998000102A/es unknown
- 1998-07-01 HR HR60/051,413A patent/HRP980377A2/hr not_active Application Discontinuation
- 1998-07-01 CO CO98037137A patent/CO4940495A1/es unknown
1999
- 1999-11-19 IS IS5260A patent/IS5260A/is unknown
- 1999-11-23 BG BG103918A patent/BG103918A/xx unknown
- 1999-12-21 OA OA9900301A patent/OA11243A/en unknown
- 1999-12-28 NO NO996520A patent/NO996520L/no not_active Application Discontinuation
2003
- 2003-06-19 AR ARP030102179A patent/AR040279A2/es unknown
- 2003-06-19 AR ARP030102180A patent/AR040280A2/es unknown

Also Published As

Publication number	Publication date
MA24587A1 (fr)	1998-12-31
UY25071A1 (es)	2000-12-29
OA11243A (en)	2003-07-24
AR015917A1 (es)	2001-05-30
EP0999829A1 (en)	2000-05-17
WO1999001120A1 (en)	1999-01-14
PE97199A1 (es)	1999-10-05
IL133076A (en)	2003-12-10
HUP0002236A3 (en)	2003-12-29
EA199900962A1 (ru)	2000-08-28
CA2290974A1 (en)	1999-01-14
AU742535B2 (en)	2002-01-03
PA8454301A1 (es)	2000-09-29
BG103918A (en)	2000-07-31
TR199903297T2 (xx)	2000-07-21
PL337804A1 (en)	2000-09-11
DZ2548A1 (fr)	2003-02-08
AR040280A2 (es)	2005-03-23
JP2000514100A (ja)	2000-10-24
YU68299A (sh)	2002-06-19
ZA985708B (en)	2000-01-10
IS5260A (is)	1999-11-19
CO4940495A1 (es)	2000-07-24
BR9810739A (pt)	2000-09-12
KR20010013365A (ko)	2001-02-26
HUP0002236A2 (hu)	2003-08-28
AR040279A2 (es)	2005-03-23
CA2290974C (en)	2004-04-27
AP9801280A0 (en)	1998-06-30
TW550087B (en)	2003-09-01
SK181099A3 (en)	2000-07-11
NO996520L (no)	2000-02-29
HN1998000102A (es)	1999-01-08
IL133076A0 (en)	2001-03-19
TNSN98124A1 (fr)	2005-03-15
NO996520D0 (no)	1999-12-28
EA002481B1 (ru)	2002-06-27
AP1192A (en)	2003-07-23
KR100366373B1 (ko)	2003-01-14
ID23429A (id)	2000-04-20
HRP980377A2 (en)	1999-04-30
AU7544898A (en)	1999-01-25
CN1261794A (zh)	2000-08-02

Publication	Publication Date	Title
Yadav et al.	2011	Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation
KR0140985B1 (ko)	1998-06-01	장기 작용성 제제에 유용한 약물 방출 조절용 피복물질
PT85819B (pt)	1990-08-31	Processo para a preparacao de membranas de revestimento e de composicoes farmaceuticas obtidas a partir delas
JP2002501016A (ja)	2002-01-15	新しい投薬形態
ES2314227T3 (es)	2009-03-16	Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
SK8252001A3 (en)	2001-12-03	Controlled release formulation of divalproex sodium
JP2015529233A (ja)	2015-10-05	医薬組成物
US11744803B2 (en)	2023-09-05	PH-controlled pulsatile delivery system, methods for preparation and use thereof
USRE42748E1 (en)	2011-09-27	Oral DTPA for radionuclide chelation
RU2181043C2 (ru)	2002-04-10	Фармацевтическая композиция для орального введения с модифицированным высвобождением, содержащая 5-аск, и способ лечения кишечных заболеваний
UA67741C2 (uk)	2004-07-15	Солюбілізовані композиції сертраліну
ES2852899T3 (es)	2021-09-14	Formulaciones estabilizadas de molindona
US20060009425A1 (en)	2006-01-12	Oral formulations of paricalcitol
ES2321908T3 (es)	2009-06-15	Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
JPH0451528B2 (no)	1992-08-19
Kouchak et al.	2004	Ion-exchange, an approach to prepare an oral floating drug delivery system for diclofenac
PT1618873E (pt)	2007-09-04	Grânulos para libertação controlada de tamsulosina, que contém alginato.
US20040208926A1 (en)	2004-10-21	Solubilized sertraline compositions
NZ501250A (en)	2003-05-30	Solubilized sertraline compositions
MXPA99012101A (en)	2000-06-01	Solubilized sertraline compositions
RU2412694C2 (ru)	2011-02-27	pH-КОНТРОЛИРУЕМЫЕ СИСТЕМЫ ИМПУЛЬСНОЙ ДОСТАВКИ, МЕТОДЫ ПОЛУЧЕНИЯ И ИХ ИСПОЛЬЗОВАНИЯ
Shah	2023	Formulation and Optimization of Delayed Release Multiunit Dosage System for The Treatment of Multiple Sclerosis
CZ464199A3 (cs)	2000-04-12	Solubilizované sertralinové kompozice
CA2578806A1 (en)	2005-12-15	Oral formulations of paricalcitol